New article on Genting/TauRx: https://www.thestar.com.my/business/business-news/2024/07/16/gentings-earnings-recovery-a-win
Here is the relevant TauRx excerpts: "
Additionally, the research house said Genting’s 20%-owned TauRx Pharmaceuticals may accelerate the group’s earnings. On July 1, 2024, TauRx said it submitted a United Kingdom Marketing Authorisation Application for its experimental drug, hydro methylthionine mesylate (HMTM) for treatment of mild cognitive impairment and mild-to-moderate stages of Alzheimer.
“We understand that TauRx ought to receive a reply by year end.
“Based on our estimates, if HMTM is approved and TauRx is valued at US$15bil.""
Additionally here is a comment from a supposed TauRx shareholder on the Genting mesage board: "Last round was rights/ warrant exercise at usd1.5b but its for the very hardcore brave shareholders like ATK to swop in n bet showhand buy very big. Taurx still has reasonably good cash level with no cash burning clinical trials anytime soon. I think next fund raising will be after securing as many CAs as possible to bring up value first, then do a pre-ipo fund raising."
.... Dundee owns 3.2% of TauRx. At the US$15B valuation that translates to C$657M to Dundee ($7.50 per DC.A share).